{"name":"Entest BioMedical","slug":"entest","ticker":"ENTX","exchange":"OTC","domain":"entestbiomedical.com","description":"Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorpora","hq":"San Diego, CA","founded":0,"employees":"20","ceo":"Roen Galloway","sector":"Veterinary Immunotherapy","stockPrice":1.32,"stockChange":0.03,"stockChangePercent":2.33,"marketCap":"$72M","metrics":{"revenue":42000,"revenueGrowth":-100,"grossMargin":0,"rdSpend":949584,"netIncome":191618,"cash":7108000,"dividendYield":0,"peRatio":-2.4,"fiscalYear":"FY2019"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"ENTX-001 patent cliff ($X.XB at risk)","drug":"ENTX-001","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"earnings","headline":"Entest BioMedical Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Entest BioMedical reported its fourth quarter and full year 2023 financial results, with revenue of $X.X million and a net loss of $Y.Y million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Entest BioMedical Announces Collaboration with Leading Veterinary Research Institution","summary":"Entest BioMedical announced a collaboration with a leading veterinary research institution to develop new treatments for companion animals.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2020-01-21","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2020-01-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2019-12-20","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2019-07-15","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2019-04-29","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2019-04-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2019-01-22","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2018-12-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2018-11-28","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2018-11-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2018-10-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2018-07-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2018-07-03","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2018-04-02","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2018-01-31","type":"earnings","source":"SEC EDGAR","summary":"SC 13G filed with SEC: SC 13G","headline":"SC 13G Filing","sentiment":"neutral"}],"patents":[{"drugName":"ENTX-001","drugSlug":"generic-name-not-publicly-disclosed","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US"}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":["Zoetis","Elanco","Merial"],"therapeuticFocus":["Immunotherapy","Veterinary Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2019-08-31","revenueHistory":[{"value":0,"period":"2019-08-31"},{"value":0,"period":"2018-08-31"},{"value":0,"period":"2018-08-31"},{"value":0,"period":"2017-08-31"},{"value":419336,"period":"2012-08-31"}],"grossProfit":0,"grossProfitHistory":[{"period":"2025-12-31","value":0},{"period":"2024-12-31","value":9000},{"period":"2023-12-31","value":0},{"period":"2022-12-31","value":33000}],"rdSpend":949584,"rdSpendHistory":[{"period":"2025-12-31","value":6004000},{"period":"2024-12-31","value":4499000},{"period":"2023-12-31","value":4510000},{"period":"2022-12-31","value":5848000}],"sgaSpend":5525000,"operatingIncome":-11529000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-11529000},{"period":"2024-12-31","value":-9585000},{"period":"2023-12-31","value":-8891000},{"period":"2022-12-31","value":-13017000}],"netIncome":191618,"netIncomeHistory":[{"period":"2025-12-31","value":-11439000},{"period":"2024-12-31","value":-9541000},{"period":"2023-12-31","value":-8889000},{"period":"2022-12-31","value":-13071000}],"eps":-0.25,"epsHistory":[{"period":"2025-12-31","value":-0.25},{"period":"2024-12-31","value":-0.25},{"period":"2023-12-31","value":-0.31},{"period":"2022-12-31","value":-0.45}],"cash":7108000,"cashHistory":[{"period":"2025-12-31","value":7108000},{"period":"2024-12-31","value":8660000},{"period":"2023-12-31","value":11019000},{"period":"2022-12-31","value":12309000}],"totalAssets":9307,"totalLiabilities":2892000,"totalDebt":490000,"equity":13101000,"operatingCashflow":-7370000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-7370000},{"period":"2024-12-31","value":-6818000},{"period":"2023-12-31","value":-7310000},{"period":"2022-12-31","value":-12499000}],"capex":-107000,"capexHistory":[{"period":"2025-12-31","value":-107000},{"period":"2024-12-31","value":-3000},{"period":"2023-12-31","value":-17000},{"period":"2022-12-31","value":-47000}],"freeCashflow":-7477000,"dividendsPaid":null,"buybacks":null,"employees":20,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":1324000,"ebit":-3042000,"ebitda":-3035000,"period":"2025-12-31","revenue":0,"epsBasic":null,"netIncome":-3016000,"rdExpense":1718000,"epsDiluted":null,"grossProfit":0,"operatingIncome":-3042000},{"sga":1613000,"ebit":-3256000,"ebitda":-3248000,"period":"2025-09-30","revenue":0,"epsBasic":-0.07,"netIncome":-3200000,"rdExpense":1643000,"epsDiluted":-0.07,"grossProfit":0,"operatingIncome":-3256000},{"sga":1148000,"ebit":-2668000,"ebitda":-2661000,"period":"2025-06-30","revenue":0,"epsBasic":-0.06,"netIncome":-2656000,"rdExpense":1520000,"epsDiluted":-0.06,"grossProfit":0,"operatingIncome":-2668000},{"sga":1440000,"ebit":-2563000,"ebitda":-2555000,"period":"2025-03-31","revenue":42000,"epsBasic":-0.06,"netIncome":-2567000,"rdExpense":1123000,"epsDiluted":-0.06,"grossProfit":0,"operatingIncome":-2563000},{"sga":1136000,"ebit":-2337000,"ebitda":-2326000,"period":"2024-12-31","revenue":82000,"epsBasic":null,"netIncome":-2358000,"rdExpense":1201000,"epsDiluted":null,"grossProfit":0,"operatingIncome":-2337000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.08,"netIncome":null,"rdExpense":null,"epsDiluted":-0.08,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1.32,"previousClose":1.29,"fiftyTwoWeekHigh":3.22,"fiftyTwoWeekLow":0.91,"fiftyTwoWeekRange":"0.91 - 3.22","fiftyDayAverage":1.21,"twoHundredDayAverage":1.79,"beta":1.55,"enterpriseValue":53990912,"forwardPE":-2.4,"priceToBook":4.64,"priceToSales":1707.92,"enterpriseToRevenue":1285.5,"enterpriseToEbitda":-4.7,"pegRatio":0,"ebitda":-11499000,"ebitdaMargin":0,"freeCashflow":-11443625,"operatingCashflow":-7370000,"totalDebt":490000,"debtToEquity":3.7,"currentRatio":6.94,"returnOnAssets":-56.8,"returnOnEquity":-108,"analystRating":"1.0 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":1,"targetMeanPrice":9,"targetHighPrice":9,"targetLowPrice":9,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":20.9,"institutionHeldPercent":17.1,"sharesOutstanding":54450028,"floatShares":32236947,"sharesShort":192781,"shortRatio":1.08,"shortPercentOfFloat":0.3,"epsTrailing":-0.26,"epsForward":-0.55,"revenuePerShare":0,"bookValue":0.28,"officers":[{"age":48,"name":"Ms. Miranda J. Toledano M.B.A.","title":"CEO & Director"},{"age":47,"name":"Dr. Hillel  Galitzer M.B.A., Ph.D.","title":"Chief Operating Officer"},{"age":48,"name":"Dr. Gregory  Burshtein Ph.D.","title":"Chief of Research & Development"},{"age":42,"name":"Ms. Dana  Yaacov-Garbeli CPA","title":"Chief Financial Officer"},{"age":null,"name":"Dr. Rachel B. Wagman","title":"Chief Clinical Advisor"},{"age":null,"name":"Ms. Cherin  Smith","title":"Executive VP & Head of Clinical Operations"},{"age":null,"name":"Dr. Constantin  Itin Ph.D., R.Ph.","title":"Head of Biopharmaceutics & Bioanalytics"}],"industry":"Biotechnology","irWebsite":"","website":"https://enterabio.com","phone":"972 2 532 7151"}}